OUTPATIENT SUBCUTANEOUS ALEMTUZUMAB IS FEASIBLE AND SAFE FOR APLASTIC ANEMIA AND ASSOCIATED WITH HIGH RESPONSE RATES

Autor: AR Fonseca, CC Justino, VC Molla, PE Yamakawa, IB Rabelo, A Hill, L Arnold, R Kelly, M Griffin, T Munir, E Velloso, T Dalessandro, AM Risitano, P Scheinberg, A Kulasekararaj, C Arrais-Rodrigues

Publikováno v: Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S17- (2023)

This multicenter international retrospective analysis aimed to evaluate the efficacy and safety of subcutaneous alemtuzumab (ALZ) as an alternative immunosuppressive therapy for aplastic anemia (AA). The study included 57 with AA patients who receive

Externí odkaz: https://doaj.org/article/9019b3e2c3ce41f898c65193ae4a950e

Fanconi Anemia

Autor: Am Risitano, Eliane Gluckman, R. Peffault de Latour

Fanconi anemia (FA) is the most frequent inherited cause of bone marrow failure. Most FA patients experience hematopoietic stem cell attrition and cytopenia during childhood. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22b54d247ca884284ecb078a64119b0a
https://doi.org/10.1016/b978-0-12-804152-9.00016-6

Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant

Autor: Patrizia Ricci, Am Risitano, G. De Rosa, L Del Vecchio, Bruno Rotoli, Jp Maciejewski, Carmine Selleri, Anna Maria Raiola, G Varriale, P Della Cioppa, Marco Picardi, Luigiana Luciano, L Pezzullo

Publikováno v: Scopus-Elsevier

We investigated bone marrow (BM) and circulating (PB) hematopoietic progenitor cells in 37 normal donors and in 25 patients 1 to 8 years after successful allogeneic bone marrow transplant. At the time of testing, transplanted patients had normal bloo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee13a70d86e8ab2f37ab705eb77fefc
https://doi.org/10.1038/sj.bmt.1701759

Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab

Autor: Am Risitano, Bianca Serio, Carmine Selleri

Acquired bone marrow failure syndromes (BMFS) are a heterogeneous group of hematological disorders characterized by impaired bone marrow function and subsequent cytopenia of one or more blood cell lineages [1,2]. The well-accepted pathogenic mechanis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d27c764825cc1d7c8b89a2db979da6
http://hdl.handle.net/11588/569386

Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT.

Autor: Passweg JR; Hematology Division, EBMT Activity Survey Office, University Hospital, Basel, Switzerland., Baldomero H; Hematology Division, EBMT Activity Survey Office, University Hospital, Basel, Switzerland. helen.baldomero@usb.ch., Alexander T; Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany., Angelucci E; Hematology and Cellular Therapy Unit. IRCCS Ospedale Policlinico San Martino, Genova, Italy., Averbuch D; Faculty of Medicine, Hebrew University of Jerusalem; Hadassah Medical Center, Jerusalem, Israel., Bazarbachi A; Department of Internal Medicine, Bone Marrow Transplantation Program, American University of Beirut, Beirut, Lebanon., Ciceri F; Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Raffaella G; Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Hazenberg MD; Department of Hematology, Amsterdam University Medical Centres, University of Amsterdam, and Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands., Kalwak K; Clinical Department of Pediatric BMT, Hematology and Oncology, Wroclaw Medical University, Wroclaw, Poland., McLornan DP; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Risitano AM; Hematology and Hematopoietic Transplant Unit, Azienda Ospedaliera di Rilievo Nazionale 'San Giuseppe Moscati' (A.O.R.N. Giuseppe Moscati), Avellino, Italy., Ruggeri A; Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy., Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Sureda A; Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Nov 22. Date of Electronic Publication: 2024 Nov 22.